专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US10121102B2 RFID tag for its arrangement on a blood-derivated products bottle and use of the same 有权
公开(公告)号：US10121102B2
公开(公告)日：2018-11-06
申请号：US15592684
申请日：2017-05-11
申请人： GRIFOLS, S.A.
发明人： Carlos Roura Fernandez , Victor Grifols Roura , Jordi Boira Bonhora
IPC分类号： G06K19/06 , G06K19/077 , A61J1/05
摘要： An RFID tag is for arrangement on a bottle for blood-derived products. The bottle includes a main body, the upper end of which includes a neck. The bottle is hermetically sealed by a cap arranged in the upper portion of the neck. The upper portion of the cap includes at least two through-pipes and at least two stiffening ribs that are each connected to the pipes by one of the respective ends thereof. The RFID tag has at least two openings shaped to fit each of the through-pipes, respectively, of the cap such that said RFID tag is positioned on the upper surface of the cap and thus overcomes the obstacle of the through-pipes and the respective stiffening ribs.

2. 发明授权

US09957315B2 Purification of cell culture derived alpha1 protease inhibitor 有权
公开(公告)号：US09957315B2
公开(公告)日：2018-05-01
申请号：US15138682
申请日：2016-04-26
申请人： Grifols, S.A.
发明人： David Ownby , Thomas P. Zimmerman , Jennifer A. Hunt , Charles Miller , Senthil Ranganathan , Tonny Dessources
IPC分类号： C12N7/00 , C12N7/01 , C12N7/02 , C12N9/99 , C12Q1/37 , A23J1/00 , C07K1/00 , C07K14/00 , C07K16/00 , C07K17/00 , C07K14/81 , C07K14/47 , C07K1/36 , C12N15/86
CPC分类号： C07K14/8125 , C07K1/36 , C07K14/4703 , C12N7/00 , C12N9/99 , C12N15/86 , C12Q1/37
摘要： Described herein are methods for purifying recombinant, cell culture derived alpha1-protease inhibitor and removing a colored species that co-purifies with the recA1PI protein. Also described are methods for reducing the iron in cell culture derived alpha1-protease inhibitor.

3. 发明授权

US09283316B2 Priming anticoagulant alignment for blood extraction 有权
标题翻译：启动抗凝血剂对齐血液提取
公开(公告)号：US09283316B2
公开(公告)日：2016-03-15
申请号：US14122726
申请日：2012-05-24
申请人： Greg Flexman
发明人： Greg Flexman
IPC分类号： A61M37/00 , A61M1/36 , A61M1/38 , A61M1/34
CPC分类号： A61M1/3672 , A61M1/3496 , A61M1/3643 , A61M1/3644 , A61M1/38
摘要： Methods and devices are described for reducing anticoagulant dilution of collected blood components during blood collection.
摘要翻译：描述了用于在采血期间减少收集的血液成分的抗凝血稀释的方法和装置。

4. 发明申请

US20140026593A1 THAWING VESSEL FOR BIOLOGICAL PRODUCTS 有权
标题翻译：用于生物产品的船舶
公开(公告)号：US20140026593A1
公开(公告)日：2014-01-30
申请号：US13803128
申请日：2013-03-14
申请人： GRIFOLS, S.A.
发明人： Ajoy VELAYUDHAN , Robert Large
IPC分类号： F28F13/12
CPC分类号： F28F13/125 , A01N1/0242 , A01N1/0284 , B01F15/06 , B01F15/063 , C12N1/04
摘要： Described herein are devices and methods for thawing frozen biological products efficiently without harming the products.
摘要翻译：本文描述的是有效地解冻冷冻生物产品而不损害产品的装置和方法。

5. 发明授权

US08376188B2 Device for the application of fibrin adhesive 有权
标题翻译：用于应用纤维蛋白粘合剂的装置
公开(公告)号：US08376188B2
公开(公告)日：2013-02-19
申请号：US12759954
申请日：2010-04-14
申请人： Jorge Maria Manzano Riera
发明人： Jorge Maria Manzano Riera
IPC分类号： B67D7/70
CPC分类号： A61B17/00491 , A61B2017/00495 , A61M5/19 , A61M5/315
摘要： A device for the application of two components of fibrin adhesive at a treatment site comprising a support for syringes comprising two parallel cylindrical housings to receive corresponding syringes and a plunger connecting member, characterised in that the said syringe support comprises a passage for insertion of the said plunger connecting member, the said passage being located in the space defined between the cylindrical housings of the said syringe support, the said plunger connector having a zone with a suitable geometry to slide within the said passage and in that the transverse cross-section of the said passage of the syringe support has a maximum opening at the ends and a minimum opening in the central part.
摘要翻译：一种用于在治疗部位应用纤维蛋白粘合剂的两个组分的装置，其包括用于注射器的支撑件，所述支架包括两个平行的圆柱形壳体以接收相应的注射器和柱塞连接构件，其特征在于，所述注射器支架包括用于插入所述柱塞连接构件，所述通道位于限定在所述注射器支撑件的圆柱形壳体之间的空间中，所述柱塞连接器具有适当几何形状的区域，以在所述通道内滑动，并且所述柱塞连接构件的横截面注射器支架的所述通道在端部具有最大开口并且在中心部分具有最小开口。

6. 发明授权

US08231599B2 Process for obtaining high efficiency human albumin for use in detoxification therapy 有权
标题翻译：获得用于解毒治疗的高效人白蛋白的方法
公开(公告)号：US08231599B2
公开(公告)日：2012-07-31
申请号：US13027447
申请日：2011-02-15
申请人： Juan Ignacio Jorquera Nieto , Pere Ristol Debart , Montserrat Costa Rierola
发明人： Juan Ignacio Jorquera Nieto , Pere Ristol Debart , Montserrat Costa Rierola
IPC分类号： A61M31/00
CPC分类号： A61K38/38 , C07K14/765
摘要： A process for detoxifying the blood of a patient in need thereof involves: collecting albumin from human plasma and/or plasma fractions; diafiltration of a mixture containing the collected albumin; stabilizing the resulting diafiltered albumin mixture with sodium chloride and an amino acid in the absence of any added fatty acid; pasteurizing the stabilized albumin mixture; diafiltering the pasteurized mixture to remove, among other things, stabilizers; and detoxifying the blood of the patient by administering the resulting albumin to the patient. In one embodiment, the amino acid stabilizing agent is acetyl tryptophan. The resulting albumin has at least about 80% albumin binding capacity relative to natural plasma albumin, and is storage stable for about 30 months at 30° C.
摘要翻译：对有需要的患者的血液进行解毒的方法包括：从人血浆和/或血浆级分中收集白蛋白; 含有收集的白蛋白的混合物的渗滤; 在不存在任何添加的脂肪酸的情况下用氯化钠和氨基酸稳定所得到的渗滤白蛋白混合物; 将稳定的白蛋白混合物巴氏消毒; 将巴氏消毒的混合物过滤，除去其它物质，以除去其中的稳定剂; 并通过将所得白蛋白给予患者来解毒患者的血液。在一个实施方案中，氨基酸稳定剂是乙酰色氨酸。所得白蛋白相对于天然血浆白蛋白具有至少约80％的白蛋白结合能力，并且在30℃下储存稳定约30个月。

7. 发明申请

US20110275570A1 PROCESS FOR OBTAINING A CONCENTRATE OF VON WILLEBRAND FACTOR OF A COMPLEX OF FACTOR VIII/VON WILLEBRAND FACTOR AND USE OF THE SAME 审中-公开
标题翻译：获得因子VIII / VON WILLEBRAND因子复合物的VON WILLEBRAND因子浓度的方法及其使用
公开(公告)号：US20110275570A1
公开(公告)日：2011-11-10
申请号：US13164117
申请日：2011-06-20
申请人： Juan Ignacio JORQUERA NIETO , Pere RISTOL DEBART , Maria Mercedes FARO TOMAS
发明人： Juan Ignacio JORQUERA NIETO , Pere RISTOL DEBART , Maria Mercedes FARO TOMAS
IPC分类号： A61K38/37 , A61P7/04
CPC分类号： C07K14/755 , A61K38/00
摘要： A method of treating a patient suffering from Haemophilia A and/or Von Willebrand's disease involves administering the patient a concentrate of Von Willebrand Factor (VWF) or a complex of Factor VIII/VWF prepared by creating a solution of VWF or a complex of Factor VIII/VWF containing VWF at a concentration of up to 12 IU VWF:RCo/ml and a VWF/Factor VIII ratio of 0.4 or more, and nanofiltering that starting solution through a filter of pore size of about 35 nm or smaller. The resulting VWF retains high molecular weight multimers.
摘要翻译：治疗患有血友病A和/或血管性血友病的患者的方法包括向患者施用Von Willebrand因子（VWF）的浓缩物或通过产生VWF或因子VIII复合物制备的因子VIII / VWF的复合物 / VWF，其浓度高达12IU VWF：RCo / ml，VWF /因子VIII比为0.4或更高，并且通过孔尺寸为约35nm或更小的过滤器对起始溶液进行纳滤。所得VWF保留高分子量多聚体。

8. 发明申请

US20110045455A1 SUSPENSION MEDIUM FOR RED BLOOD CELLS 审中-公开
标题翻译：红血球细胞悬浮液
公开(公告)号：US20110045455A1
公开(公告)日：2011-02-24
申请号：US12915346
申请日：2010-10-29
申请人： Daniel Martorell Pena , Ma del Carmen Traves Polo , Jordi Farre Leon , Josefina Castells Parera
发明人： Daniel Martorell Pena , Ma del Carmen Traves Polo , Jordi Farre Leon , Josefina Castells Parera
IPC分类号： A01N1/02
CPC分类号： G01N33/80 , A01N1/02 , A01N1/0226 , G01N33/96 , Y10T436/108331
摘要： The present invention relates to a new suspension medium or diluent solution for red blood cells for use in haematological methods. The suspension medium or diluent solution for red blood cells may comprise a combination of two or more amino acids of any group, and preserves the red blood cells in the sample for at least 8 weeks.
摘要翻译：本发明涉及用于血液学方法的用于红细胞的新的悬浮液或稀释剂溶液。用于红细胞的悬浮介质或稀释液可以包含任何组的两个或多个氨基酸的组合，并且将样品中的红细胞保存至少8周。

9. 发明申请

US20100159017A1 COMPOSITION OF BIOCOMPATIBLE MICROPARTICLES OF ALGINIC ACID FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS BY INTRAVENOUS ADMINISTRATION 有权
标题翻译：通过静脉内给药控制释放活性成分的生物活性微生物的组成
公开(公告)号：US20100159017A1
公开(公告)日：2010-06-24
申请号：US12634203
申请日：2009-12-09
申请人： Salvador GRANCHA GAMON , Anna Nardi Ricart , Josep Mariá Suñe Negre , Josep Ramón Tico Grau , Montserrat Miñarro Carmona
发明人： Salvador GRANCHA GAMON , Anna Nardi Ricart , Josep Mariá Suñe Negre , Josep Ramón Tico Grau , Montserrat Miñarro Carmona
IPC分类号： A61K9/62 , A61K38/02 , A61K38/37 , A61K38/17 , A61P7/04 , A61P5/00 , A61K38/36 , B29B9/00
CPC分类号： A61K38/37 , A61K9/0019 , A61K9/5036 , A61K9/5089 , A61K38/4846
摘要： The invention relates to a biocompatible composition which comprises microparticles of alginic acid or its salts and an active ingredient. More particularly, the invention relates to microparticles for the encapsulation of an active ingredient to be administered intravenously to a patient who needs it. These microparticles are of a combination of size sufficient to increase the half-life or survival of the active ingredient in blood, with a low uptake in the liver and a fast cell clearance when administered intravenously.
摘要翻译：本发明涉及包含藻酸或其盐的微粒和活性成分的生物相容性组合物。更具体地，本发明涉及用于将待静脉内施用的活性成分包封的微粒用于需要它的患者。这些微粒具有足以增加血液中活性成分的半衰期或存活的尺寸的组合，在肝脏中摄取量低，并且静脉内施用时具有快速的细胞清除率。

10. 发明授权

US07442308B2 Process for removing viruses in fibrinogen solutions and fibrinogen obtained by said process 有权
标题翻译：通过所述方法获得的纤维蛋白原溶液和纤维蛋白原中除去病毒的方法
公开(公告)号：US07442308B2
公开(公告)日：2008-10-28
申请号：US10788049
申请日：2004-02-25
申请人： Pere Ristol Debart , Jesus Fernandez Rodriguez
发明人： Pere Ristol Debart , Jesus Fernandez Rodriguez
IPC分类号： B01D61/58 , B01D61/14 , A61K35/16 , B01D61/00 , A61K35/00
CPC分类号： C07K14/75 , A61K38/363 , A61L2/0017 , C07K1/34
摘要： A process for removing viruses in fibrinogen solutions and fibrinogen obtained thereof wherein the process starts with an adjusted purified fibrinogen solution, the adjusted purified solution is frozen and then thawed at a temperature between 5 and 20° C., the undissolved materials associated with the fibrinogen are subsequently separated, the temperature is adjusted and the resultant solution is finally subjected to nanofiltration using filters having a pore size smaller than 35 nm.
摘要翻译：一种用于从纤维蛋白原溶液中除去病毒的方法及其获得的纤维蛋白原，其中该方法以经调整的纯化纤维蛋白原溶液开始，将经调节的纯化溶液冷冻，然后在5至20℃的温度下解冻，与纤维蛋白原相关的未溶解物质随后分离，调节温度，最后使用孔径小于35nm的过滤器对所得溶液进行纳滤。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式